title: Role of cathepsin A and lysosomes in the intracellular activation of novel antipapillomavirus agent GS-9191.
abstract: GS-9191, a bis-amidate prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine (cPrPMEDAP), was designed as a topical agent for the treatment of papillomavirus-associated proliferative disorders, such as genital warts. In this study, we investigated the mechanism of conversion of GS-9191 to cPrPMEDAP. We observed that GS-9191 is hydrolyzed in the presence of the lysosomal carboxypeptidase cathepsin A (CatA) in vitro and is less efficiently metabolized in CatA-deficient fibroblasts than in control cells. In addition, knockdown of CatA by small interfering RNA (siRNA) reduced the intracellular accumulation of GS-9191 metabolites. However, intracellular CatA levels did not correlate with the susceptibility of tested cell lines to GS-9191, indicating that the CatA step is unlikely to be rate limiting for the activation of GS-9191. Further analysis showed that upon the hydrolysis of the carboxylester bond in one of the GS-9191 amidate moieties, the unmasked carboxyl group displaces L-phenylalanine 2-methylpropyl ester from the other amidate moiety. The cPrPMEDAP-L-phenylalanine conjugate (cPrPMEDAP-Phe) formed is not metabolized by Hint1 (histidine triad nucleotide binding protein 1) phosphoramidase but undergoes spontaneous degradation to cPrPMEDAP in acidic pH that can be significantly enhanced by the addition of SiHa cell extract. Pretreatment of SiHa cells with bafilomycin A or chloroquine resulted in an 8-fold increase in the intracellular concentration of cPrPMEDAP-Phe metabolite and the accumulation of GS-9191 metabolites in the lysosomal/endosomal fraction. Together, these observations indicate that the conversion of GS-9191 to cPrPMEDAP occurs in lysosomes via CatA-mediated ester cleavage, followed by the release of cPrPMEDAP, most likely through the combination of enzyme-driven and spontaneous pH-driven hydrolysis of a cPrPMEDAP-Phe intermediate.
authors.affiliation: Biology Department, Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA. Gabriel_Birkus@gilead.com
authors.forename: Gabriel
authors.initials: G
authors.lastname: Birkus
authors.forename: Nilima
authors.initials: N
authors.lastname: Kutty
authors.forename: Christian R
authors.initials: CR
authors.lastname: Frey
authors.forename: Riri
authors.initials: R
authors.lastname: Shribata
authors.forename: Tsuifen
authors.initials: T
authors.lastname: Chou
authors.forename: Carston
authors.initials: C
authors.lastname: Wagner
authors.forename: Martin
authors.initials: M
authors.lastname: McDermott
authors.forename: Tomas
authors.initials: T
authors.lastname: Cihlar
mesh_terms: D000998:Antiviral Agents / Q000378:metabolism / Q000494:pharmacology*; D043402:Cathepsin A / Q000235:genetics / Q000378:metabolism*; D045744:Cell Line, Tumor; D002738:Chloroquine / Q000494:pharmacology; D005260:Female; D006367:HeLa Cells; D006801:Humans; D006863:Hydrogen-Ion Concentration; D015151:Immunoblotting; D008247:Lysosomes / Q000378:metabolism*; D018942:Macrolides / Q000494:pharmacology; D027383:Papillomaviridae / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism*; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D002583:Uterine Cervical Neoplasms / Q000821:virology
chemical_list: D000998:Antiviral Agents; C543852:GS-9191; D018942:Macrolides; C057620:bafilomycin A; D010649:Phenylalanine; D002738:Chloroquine; D043402:Cathepsin A